These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 30519894)

  • 1. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
    Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
    Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
    Nassehi D
    Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas.
    Oya S; Kawai K; Nakatomi H; Saito N
    J Neurosurg; 2012 Jul; 117(1):121-8. PubMed ID: 22559847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.
    Bernatz S; Monden D; Gessler F; Radic T; Hattingen E; Senft C; Seifert V; Ronellenfitsch MW; Plate KH; Harter PN; Baumgarten P
    J Mol Histol; 2021 Apr; 52(2):233-243. PubMed ID: 33528717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dural detachment on long-term tumor control for meningiomas treated using Simpson grade IV resection.
    Fukushima Y; Oya S; Nakatomi H; Shibahara J; Hanakita S; Tanaka S; Shin M; Kawai K; Fukayama M; Saito N
    J Neurosurg; 2013 Dec; 119(6):1373-9. PubMed ID: 24053497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
    Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
    Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade.
    Mahzouni P; Movahedipour M
    Pathol Res Pract; 2012 Apr; 208(4):221-4. PubMed ID: 22420924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
    Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
    Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. World Health Organization Grade II Meningiomas: The Role of Adjuvant/Salvage Gamma Knife Surgery After Initial Surgery and Prognostic Factor Assessment.
    Liu X; Shan B; Wang M; Xu J
    World Neurosurg; 2018 Jan; 109():e352-e362. PubMed ID: 28987849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
    Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin expressions correlate with WHO grades and predict recurrence in meningiomas.
    Arikök AT; Onder E; Seçkin H; Kaçar A; Fesli R; Oğuz AS; Alper M
    Brain Tumor Pathol; 2014 Apr; 31(2):94-100. PubMed ID: 23793814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alterations associated with progression and recurrence in meningiomas.
    Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
    J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas.
    Sughrue ME; Kane AJ; Shangari G; Rutkowski MJ; McDermott MW; Berger MS; Parsa AT
    J Neurosurg; 2010 Nov; 113(5):1029-35. PubMed ID: 20380529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and prognostic factors of WHO II and III adult spinal meningiomas: analysis of 25 cases in a single center.
    Ye J; Lv G; Qian J; Zhu J; Han R; Luo C
    J Neurooncol; 2016 Jun; 128(2):349-56. PubMed ID: 27056111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.